Do analysts rate SNTI or EXOZ?

Senti Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 2,765.33%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Senti Biosciences is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or EXOZ more profitable?

eXoZymes' return on equity of -220.63% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% eXoZymes N/A -220.63% -141.26%

Is SNTI or PDSB more profitable?

PDS Biotechnology's return on equity of -346.02% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% PDS Biotechnology N/A -346.02% -102.36%

Senti Biosciences (SNTI) Competitors

$0.35 0.00 (-1.33%)

As of 04:00 PM Eastern

Compare

SNTI vs. MGX, EXOZ, GOSS, PDSB, and DYAI

Should you buy Senti Biosciences stock or one of its competitors? Senti Biosciences's main competitors and comparable companies include Metagenomi (MGX), eXoZymes (EXOZ), Gossamer Bio (GOSS), PDS Biotechnology (PDSB), and Dyadic International (DYAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Senti Biosciences compare to Metagenomi?

Senti Biosciences (NASDAQ:SNTI) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, Metagenomi had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Metagenomi and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Overall Sentiment
Senti Biosciences	Neutral
Metagenomi	Neutral

Senti Biosciences has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Senti Biosciences has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	543.57	-$61.44M	-$1.92	N/A
Metagenomi	$25.21M	1.84	-$87.87M	-$2.30	N/A

Senti Biosciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Metagenomi	-384.61%	-51.23%	-36.62%

Senti Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 2,765.33%. Metagenomi has a consensus target price of $7.00, suggesting a potential upside of 469.11%. Given Senti Biosciences' higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

25.7% of Senti Biosciences shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Senti Biosciences beats Metagenomi on 8 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to eXoZymes?

Senti Biosciences (NASDAQ:SNTI) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Senti Biosciences has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, indicating that its stock price is 193% more volatile than the broader market.

In the previous week, eXoZymes had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Senti Biosciences. eXoZymes' average media sentiment score of 0.85 beat Senti Biosciences' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Senti Biosciences	Neutral
eXoZymes	Positive

Senti Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 2,765.33%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Senti Biosciences is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

eXoZymes has higher revenue and earnings than Senti Biosciences. eXoZymes is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	543.57	-$61.44M	-$1.92	N/A
eXoZymes	$70K	684.17	-$9.16M	-$1.14	N/A

eXoZymes' return on equity of -220.63% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
eXoZymes	N/A	-220.63%	-141.26%

Summary

eXoZymes beats Senti Biosciences on 9 of the 16 factors compared between the two stocks.

How does Senti Biosciences compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Senti Biosciences has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.79	N/A
Senti Biosciences	$20K	543.57	-$61.44M	-$1.92	N/A

Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

Gossamer Bio presently has a consensus price target of $3.20, indicating a potential upside of 1,717.15%. Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 2,765.33%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Gossamer Bio had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Gossamer Bio and 0 mentions for Senti Biosciences. Gossamer Bio's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Gossamer Bio	Neutral
Senti Biosciences	Neutral

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Senti Biosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Senti Biosciences	N/A	-532.05%	-103.35%

Summary

Gossamer Bio and Senti Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Senti Biosciences compare to PDS Biotechnology?

Senti Biosciences (NASDAQ:SNTI) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 2,765.33%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 1,131.02%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Senti Biosciences is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology's return on equity of -346.02% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
PDS Biotechnology	N/A	-346.02%	-102.36%

PDS Biotechnology has lower revenue, but higher earnings than Senti Biosciences. PDS Biotechnology is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	543.57	-$61.44M	-$1.92	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, PDS Biotechnology had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for PDS Biotechnology and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Senti Biosciences	Neutral
PDS Biotechnology	Neutral

Senti Biosciences has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

PDS Biotechnology beats Senti Biosciences on 7 of the 13 factors compared between the two stocks.

How does Senti Biosciences compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Dyadic International had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Dyadic International and 0 mentions for Senti Biosciences. Dyadic International's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Senti Biosciences	Neutral

Dyadic International has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market.

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 201.45%. Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 2,765.33%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Senti Biosciences has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Senti Biosciences' return on equity of -532.05% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Senti Biosciences	N/A	-532.05%	-103.35%

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dyadic International has higher revenue and earnings than Senti Biosciences. Dyadic International is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$1.67M	21.68	-$7.36M	-$0.23	N/A
Senti Biosciences	$20K	543.57	-$61.44M	-$1.92	N/A

Summary

Senti Biosciences beats Dyadic International on 8 of the 15 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.87M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.18	9.13	269.75	24.74
Price / Sales	543.57	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.94	17.66	11.27	6.42
Net Income	-$61.44M	-$13.25M	$3.45B	$347.12M
7 Day Performance	-5.70%	5.36%	3.56%	2.48%
1 Month Performance	-66.12%	-1.74%	-0.58%	-1.04%
1 Year Performance	-77.91%	61.36%	77.52%	23.22%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	1.9956 of 5 stars	$0.35 -1.3%	$10.00 +2,765.3%	-77.6%	$10.87M	$20K	N/A	4	Gap Up
MGX Metagenomi	3.0784 of 5 stars	$1.21 flat	$7.00 +478.5%	-35.9%	$45.55M	$25.21M	N/A	236	News Coverage Earnings Report Upcoming Earnings
EXOZ eXoZymes	0.522 of 5 stars	$4.62 +0.4%	N/A	-48.1%	$42.37M	$70K	N/A	29	Gap Up
GOSS Gossamer Bio	2.1183 of 5 stars	$0.18 +4.6%	$3.20 +1,663.1%	-89.9%	$40.74M	$48.47M	N/A	180
PDSB PDS Biotechnology	1.6653 of 5 stars	$0.72 +0.8%	$9.00 +1,150.0%	-30.2%	$39.95M	N/A	N/A	20	Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. MGX, EXOZ, GOSS, PDSB, and DYAI

How does Senti Biosciences compare to Metagenomi?

Summary

How does Senti Biosciences compare to eXoZymes?

Summary

How does Senti Biosciences compare to Gossamer Bio?

Summary

How does Senti Biosciences compare to PDS Biotechnology?

Summary

How does Senti Biosciences compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. MGX, EXOZ, GOSS, PDSB, and DYAI

How does Senti Biosciences compare to Metagenomi?

Does the media prefer SNTI or MGX?

Which has more risk & volatility, SNTI or MGX?

Which has preferable valuation & earnings, SNTI or MGX?

Is SNTI or MGX more profitable?

Do analysts prefer SNTI or MGX?

Do institutionals and insiders have more ownership in SNTI or MGX?

Summary

How does Senti Biosciences compare to eXoZymes?

Which has more risk and volatility, SNTI or EXOZ?

Does the media favor SNTI or EXOZ?

Do analysts rate SNTI or EXOZ?

Do institutionals & insiders hold more shares of SNTI or EXOZ?

Which has better valuation & earnings, SNTI or EXOZ?

Is SNTI or EXOZ more profitable?

Summary

How does Senti Biosciences compare to Gossamer Bio?

Which has preferable earnings & valuation, GOSS or SNTI?

Which has more volatility & risk, GOSS or SNTI?

Do analysts recommend GOSS or SNTI?

Does the media refer more to GOSS or SNTI?

Do institutionals and insiders believe in GOSS or SNTI?

Is GOSS or SNTI more profitable?

Summary

How does Senti Biosciences compare to PDS Biotechnology?

Do institutionals & insiders hold more shares of SNTI or PDSB?

Do analysts recommend SNTI or PDSB?

Is SNTI or PDSB more profitable?

Which has higher valuation & earnings, SNTI or PDSB?

Does the media prefer SNTI or PDSB?

Which has more volatility and risk, SNTI or PDSB?

Summary

How does Senti Biosciences compare to Dyadic International?

Does the media refer more to DYAI or SNTI?

Which has more risk and volatility, DYAI or SNTI?

Do analysts rate DYAI or SNTI?

Is DYAI or SNTI more profitable?

Do institutionals and insiders have more ownership in DYAI or SNTI?

Which has better valuation and earnings, DYAI or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools